Cargando…

‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury

Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Gareth R, Mitsialis, S. Alex, Kourembanas, Stella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876073/
https://www.ncbi.nlm.nih.gov/pubmed/28985201
http://dx.doi.org/10.1038/pr.2017.256
_version_ 1783310455990648832
author Willis, Gareth R
Mitsialis, S. Alex
Kourembanas, Stella
author_facet Willis, Gareth R
Mitsialis, S. Alex
Kourembanas, Stella
author_sort Willis, Gareth R
collection PubMed
description Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonary and neurological impairment prevail in constituting the major adverse outcomes for neonatal intensive care unit (NICU) survivors. With no single effective therapy for either the prevention or treatment of such neonatal disorders, the need for new tools to treat and reduce risk of further complications associated with extreme preterm birth is urgent. Mesenchymal stem/stromal cell (MSC)-based approaches have shown promise in numerous experimental models of lung injury relevant to neonatology. Recent studies have highlighted that the therapeutic potential of MSCs is harnessed in their secretome, and that the therapeutic vector therein is represented by the exosomes released by MSCs. In this review, we summarize the development and significance of stem cell-based therapies for neonatal diseases, focusing on preclinical models of neonatal lung injury. We emphasize the development of MSC exosome-based therapeutics and comment on the challenges in bringing these promising interventions to clinic.
format Online
Article
Text
id pubmed-5876073
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-58760732018-05-22 ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury Willis, Gareth R Mitsialis, S. Alex Kourembanas, Stella Pediatr Res Article Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonary and neurological impairment prevail in constituting the major adverse outcomes for neonatal intensive care unit (NICU) survivors. With no single effective therapy for either the prevention or treatment of such neonatal disorders, the need for new tools to treat and reduce risk of further complications associated with extreme preterm birth is urgent. Mesenchymal stem/stromal cell (MSC)-based approaches have shown promise in numerous experimental models of lung injury relevant to neonatology. Recent studies have highlighted that the therapeutic potential of MSCs is harnessed in their secretome, and that the therapeutic vector therein is represented by the exosomes released by MSCs. In this review, we summarize the development and significance of stem cell-based therapies for neonatal diseases, focusing on preclinical models of neonatal lung injury. We emphasize the development of MSC exosome-based therapeutics and comment on the challenges in bringing these promising interventions to clinic. 2017-11-22 2018-01 /pmc/articles/PMC5876073/ /pubmed/28985201 http://dx.doi.org/10.1038/pr.2017.256 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Willis, Gareth R
Mitsialis, S. Alex
Kourembanas, Stella
‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title_full ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title_fullStr ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title_full_unstemmed ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title_short ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
title_sort ‘good things come in small packages’: application of exosome-based therapeutics in neonatal lung injury
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876073/
https://www.ncbi.nlm.nih.gov/pubmed/28985201
http://dx.doi.org/10.1038/pr.2017.256
work_keys_str_mv AT willisgarethr goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury
AT mitsialissalex goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury
AT kourembanasstella goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury